Renovo Scar Prevention Drug Juvista Set For Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm targets optimal dosing, awaits regulatory go-ahead.
You may also be interested in...
Phase III Data With Scar Therapy Still Distant, Renovo Draws A Suitor
Pivotal results not due until 2011 – and skin peel drug needs a makeover.
Phase III Data With Scar Therapy Still Distant, Renovo Draws A Suitor
Pivotal results not due until 2011 – and skin peel drug needs a makeover.
Shire Gains Renovo’s Skin Scarring Candidate Through Licensing Deal
Total value of the deal could reach $825 million, pending regulatory approval and sales milestones.